UPDATE: BMO Capital Markets Downgrades NuVasive on Multiple Positive Factors
July 15, 2013 at 11:16 AM EDT
In a report published Monday, BMO Capital Markets analyst Joanne K. Wuensch downgraded NuVasive (NASDAQ: NUVA ) from Market Perform to Underperform, but raised the price target from $18.00 to $22.00. In the report, BMO Capital Markets noted, “We are downgrading shares of NUVA to Underperform from Market Perform, given 1)
